Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Llibre

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Brain : a Journal of Neurology|February 4, 2025
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onsetHaiyan Liu, Thomas W Marsh, Xinyu Shi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 27, 2024
Advancements in dementia research, diagnostics, and care in Latin America: Highlights from the 2023 Alzheimer's Association International conference satellite symposium in Mexico CityAna Luisa Sosa, Sonia Md Brucki, Lucia Crivelli, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 7, 2020
The impact of SARS-CoV-2 in dementia across Latin America: A call for an urgent regional plan and coordinated responseAgustin Ibanez, Hernando Santamaria-Garcia, Alejandra Guerrero Barragan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
JAMA Psychiatry|January 22, 2025
Depressive Symptoms and Amyloid PathologyWietse A Wiels, Julie E Oomens, Sebastiaan Engelborghs, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Brain : a Journal of Neurology|February 4, 2025
The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onsetHaiyan Liu, Thomas W Marsh, Xinyu Shi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 27, 2024
Advancements in dementia research, diagnostics, and care in Latin America: Highlights from the 2023 Alzheimer's Association International conference satellite symposium in Mexico CityAna Luisa Sosa, Sonia Md Brucki, Lucia Crivelli, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Alzheimer'S & Dementia (New York, N. Y.)|December 7, 2020
The impact of SARS-CoV-2 in dementia across Latin America: A call for an urgent regional plan and coordinated responseAgustin Ibanez, Hernando Santamaria-Garcia, Alejandra Guerrero Barragan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 21, 2024
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stageNelly Joseph-Mathurin, Rebecca L Feldman, Ruijin Lu, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
JAMA Psychiatry|January 22, 2025
Depressive Symptoms and Amyloid PathologyWietse A Wiels, Julie E Oomens, Sebastiaan Engelborghs, et al.
Pageof 15